HIV-1 envelope subregion length variation during disease progression
about
Bottlenecks in HIV-1 transmission: insights from the study of founder virusesIdentification of a cluster of HIV-1 controllers infected with low replicating virusesThe V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral loadHIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Phenotypic properties of transmitted founder HIV-1Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.Characterization of HIV-1 envelopes in acutely and chronically infected injection drug usersHIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry.HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages.Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationNoninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon.Contrasting antibody responses to intrasubtype superinfection with CRF02_AG.HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients.Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsInduction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.Neutralizing antibodies and control of HIV: moves and countermoves.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.Host and Viral Factors in HIV-Mediated Bystander Apoptosis.Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by α4β7 integrin.Molecular Features of the V1-V4 Coding Region of Sexually Transmitted Human Immunodeficiency Virus Type 1.High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.
P2860
Q28082862-BBDD2744-6B7B-4DB8-8ECB-2EE8EC590987Q28534737-74DBD8A8-9B66-4E8D-9305-1AD8C84A7D3CQ30152923-1EFFE9FB-534B-4CDC-B092-C7B3BADBE316Q30353580-ECCC4EE8-0B83-4E2A-9C08-356461B8E780Q30363755-6AD444BB-C06E-4FF9-AED0-E800D2A59E68Q30393763-94AF674E-BA45-4780-BEE3-8C6E6CC808CFQ33592001-2E25923A-74E4-4D7B-B909-29BFE92922A2Q34029430-14C257D1-2BAC-4F57-9181-06C17EDC029BQ34200095-545C9287-97EC-443F-BF99-EACFC7285AA8Q34309493-F39D3BDC-DA35-40E7-B534-35C3FA172988Q34336058-0BFB0290-0FB6-420A-BA08-AA18B8E87D06Q34407843-3C68BC86-6669-4B05-9FE5-21DBE2E117C0Q34620235-19E6C5D1-2D21-4E62-84BC-AEFA359889D1Q34924647-02074253-D057-4E72-AAB5-FC85595DF246Q35113720-447AEA70-CF48-43A1-8891-C50981DB8E62Q35161426-629FE54D-33F7-499F-8EDC-002B556DCB53Q35192915-FEF99C90-CB28-4854-8FEB-92EB2156E0D1Q35216488-9F18199C-7EB8-4048-A32A-621618931E3BQ35826458-D6F2E0D7-E311-4659-B00D-B76E0CF7DF09Q35943521-7E7172A9-7360-4D0E-B691-54899172EB3DQ36000722-8AADE562-6830-46B4-AE81-CDD149B27881Q36081789-14D04E6C-6D79-45A5-A06A-D179720A2D03Q36246353-A30A4E77-6D62-4393-B72D-5BF76C983CF2Q36306344-0E735F8D-3749-4E67-82EC-2BFE20B52057Q36553805-87FCAF41-E351-47F6-B7A3-66CB69B9A9FEQ36978861-610E7231-6B33-4EDF-AFD1-C4975DC4F4E7Q37233074-CF468963-A4B7-465E-9F25-767D0D409DE1Q37252966-8829DE5C-9E3C-4BEE-8E44-CAB17F447244Q37360774-B3D6F305-BFC0-49DF-A254-EFE918E33794Q37536431-DE040077-38A0-47C0-A84C-03A28D01836DQ37971867-8D53DCA7-1F45-4C9B-8784-C994A34D3CD0Q38046828-166C03EF-656A-40CD-A552-19C3F5F16DFDQ38079744-5B10E9B7-6CCB-4F25-A834-D1917B2924C9Q38243948-E832F907-465E-46FF-B266-E172DA41E51AQ38961133-81571621-D5B4-4466-9542-B6B5C244377FQ39398170-408A4FAF-1E3C-4ACC-93C7-FABAF07D94C3Q40075506-3626DEBD-1124-4894-AA30-02F8175412D3Q40174150-526CE993-2CDE-4F0E-846D-0983E7BC2DE4Q40238313-C920C903-828E-453A-AF3C-CB857EC38A12Q40548483-F00E373B-7EAE-4D52-AC7E-398A88BCE7E8
P2860
HIV-1 envelope subregion length variation during disease progression
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
HIV-1 envelope subregion length variation during disease progression
@ast
HIV-1 envelope subregion length variation during disease progression
@en
type
label
HIV-1 envelope subregion length variation during disease progression
@ast
HIV-1 envelope subregion length variation during disease progression
@en
prefLabel
HIV-1 envelope subregion length variation during disease progression
@ast
HIV-1 envelope subregion length variation during disease progression
@en
P2093
P2860
P1433
P1476
HIV-1 envelope subregion length variation during disease progression
@en
P2093
James I Mullins
Marcel E Curlin
Rafael Zioni
Stephen E Hawes
Wenjie Deng
P2860
P304
P356
10.1371/JOURNAL.PPAT.1001228
P577
2010-12-16T00:00:00Z